Blog

Announcing New Gamma Knife Perfexion at SDGKC

November 21st, 2011

San Diego Gamma Knife Center Offers New,  Non-Invasive Surgery for the Brain

 (La Jolla, CA, 11/21/2011)  In its continuing effort to offer the best in medical care to the San Diego community, San Diego Gamma Knife Center is pleased to announce the acquisition and installation of a state-of-the-art Gamma Knife® Perfexion™. 

 “Perfexion has become the new gold standard for cranial radiosurgery, providing a level of accuracy and precision in the treatment of brain tumors, vascular malformations, and other brain disorders that is far superior to any other radiosurgery system,” explains Neurosurgery Medical Director Kenneth Ott, M.D., F.A.C.S. Perfexion also incorporates significant safety advances.  According to Radiation Oncology Medical Director David Hodgens, M.D., F.A.C.R., “The radiation dose to normal brain and to other parts of the body is far lower than any other radiosurgery system.”

 Gamma Knife is not a knife at all, and no incisions are made.  Its highly focused beams of gamma radiation offer the precision of surgery, without a scalpel and without the usual risks of surgery or an incision.

Non-Invasive Surgery

 Fueled by research and peer-reviewed published results, there is a groundswell of support for Gamma Knife radiosurgery.  Over 600,000 patients have been treated with the Gamma Knife worldwide. 

 Patients are attracted by its non-invasive nature, same day outpatient procedure and documented clinical results.  Following Gamma Knife radiosurgery, most patients resume normal activities within a day of treatment.

 Gamma Knife Perfexion delivers a single, high dose of ionizing radiation emanating from 192 cobalt-60 sources.  Gamma Knife surgeons guide the gamma irradiation to a target previously defined by advanced imaging techniques.  At this point, where all the beams simultaneously intersect, Perfexion dispenses a precise radiation dose to treat a target as intended by the physician.  Perfexion represents the latest advance by Elekta, the Gamma Knife manufacturer, in providing cutting edge tools for brain surgery.

 The alternative to treatment with Gamma Knife radiosurgery is traditional surgery, which involves certain risks and complications.  In many cases, it is impossible to surgically treat tumors that are deep-seated or situated close to critical parts of the brain such as the spinal cord or the visual and auditory cortexes.  Following traditional surgery, the patient must remain in the hospital’s intensive care unit for several days and in the neurosurgical department for a further 2-3 weeks.  The convalescence period may be several more months.

 About San Diego Gamma Knife Center

Having treated over 3,500 patients, San Diego Gamma Knife Center is an established center of excellence on the campus of Scripps Memorial Hospital La Jolla.  Since opening in 1994, the Center has been a leading radiosurgery resource for neurosurgeons and radiation oncologists throughout Southern California, Nevada and Arizona.  

 San Diego Gamma Knife Center is the region’s exclusive facility offering Gamma Knife radiosurgery for brain tumors and other brain abnormalities. U.S. News & World Report has named San Diego Gamma Knife Center’s Medical Directors, Kenneth Ott, M.D., and David Hodgens, M.D., as top honorees in their respective fields of neurosurgery and radiation oncology.

 For more information, please visit our website at www.sdgkc.com, or call

800-924-2662.

 # # #

Cell Phones & Cancer Risk: A Fact Sheet from National Cancer Institute. What do YOU think?

June 29th, 2011

Cell Phones and Cancer Risk

Key Points

  • Cell phones emit radiofrequency energy. Concerns have been raised that this energy from cell phones may pose a cancer risk to users (see Question 1).
  • Radiofrequency energy is a form of non-ionizing electromagnetic radiation; exposure depends upon the technology of the phone, distance between the phone’s antenna and the user, the extent and type of use, and distance of the user from base stations (see Question 2).
  • Researchers are studying tumors of the brain and central nervous system and other sites of the head and neck because cell phones are typically held next to the head when used (see Question 3).
  • Research studies have not shown a consistent link between cell phone use and cancer. A large international study (Interphone) published in 2010 found that, overall, cell phone users are at lower risk for two of the most common types of brain tumorglioma and meningioma―compared to non-users. For the small proportion of study participants who reported the most total time on cell phone calls, there was some increased risk of glioma, but the researchers considered this finding inconclusive (see Question 3).
  • Further research is needed to investigate possible health effects in children and persons who have used cell phones heavily for many years. 

  1. Why is there concern that cell phones may cause cancer or other health problems?There are three main reasons why people are concerned that cell phones (also known as “wireless” or “mobile” telephones) may cause certain types of cancer or other health problems:
    • The number of cell phone users has increased rapidly. As of 2010, there were more than 303 million subscribers to cell phone service in the United States, according to the Cellular Telecommunications and Internet Association. This is an increase from 110 million users in 2000. Globally, the number of cell phone subscriptions is estimated to be 5 billion.
    • Over time, the number of cell phone calls per day, the length of each call, and the duration of use of cell phones have increased and cell phone technology has undergone substantial change. Cell phone use began in Japan in 1979, in Nordic countries in Europe in 1981, and in the United States in 1983, but cell phones were not widely used in the United States until the 1990s.
    • Cell phones emit radiofrequency energy (radio waves), which is a form of non-ionizing radiation. The tissues next to where the phone is held absorb this energy. Potential health effects of radiofrequency exposure from cell phones, radar, satellite stations, microwave ovens, and other sources have been studied for many years. 
  2. What is radiofrequency energy, how can it affect the body, and how is it measured in epidemiologic studies?Radiofrequency energy is a form of electromagnetic radiation. Electromagnetic radiation can be divided into two types: ionizing (x-rays, radon, cosmic rays) and non-ionizing (radiofrequency, extremely low-frequency or power frequency). Ionizing radiation, such as that produced by x-ray machines, can pose a cancer risk. There is currently no consistent evidence that non-ionizing radiation emitted by cell phones is associated with cancer risk.When a call is placed from a cell phone, the antenna of the phone sends a signal to the nearest base station antenna. The base station routes the call through a switching center, where the call can be transferred to another cell phone, another base station, or the local land-line telephone system.

    How does radiofrequency energy affect the body? The farther a cell phone is from a base station antenna, the higher the power level needed to maintain a connection. The amount of radiofrequency energy exposure to the user decreases significantly with increasing distances between the phone’s antenna and the user, and, to a lesser extent, shorter distances between the phone and a base station. A cell phone user’s level of exposure depends on several factors, including the following:

    • The number and duration of calls
    • The amount of cell phone traffic at a given time
    • The distance from the nearest base station
    • The quality of the cellular transmission
    • The size of the handset
    • For older phones, how far the antenna is extended
    • Whether or not a hands-free device is used

    The only known biologic effect of radiofrequency energy is heating. A form of this kind of energy is used by microwave ovens. Although high doses of radiofrequency energy cause localized tissue heating, the level of radiofrequency exposure from cell phone use is not sufficient to increase body temperature. There is no consistent evidence that radiofrequency exposure can produce other serious health effects, including cancer. However, more research is needed to determine what effects, if any, this energy has on the body.

    How is radiofrequency energy measured in epidemiologic studies? Two strategies have been used to estimate radiofrequency levels in epidemiologic studies. Radiofrequency levels are estimated by assessing the following information from in-person interviews or self-administered questionnaires:

    • Whether the subject was a “regular” user (minimum number of calls per week/month)
    • The age/year of first use and age/year of last use (duration of use and time since start of use)
    • The average number of cell phone calls per day/week/month (frequency)
    • The average length of a typical cell phone call
    • Total hours of lifetime use, calculated from length of typical call times, number of calls per period, and duration of use 
  3. Do cell phones cause cancer? What is the scientific evidence, and what do expert reviewers conclude?There is concern that radiofrequency energy produced by cell phones may affect the brain and other tissues in the head because hand-held cell phones are usually operated close to the head. Researchers have focused on whether radiofrequency energy can cause malignant (cancerous) brain tumors, such as gliomas as well as benign (noncancerous) tumors, such as acoustic neuromas (tumors in the cells of the nerve responsible for hearing), meningiomas (tumors in the meninges, membranes that cover and protect the brain and spinal cord), and parotid gland tumors (tumors in the salivary glands). Researchers have investigated the possible role of cell phones or other sources of radiofrequency exposure and cancer risks in humans and animals. There are also experimental investigations assessing potential biologic or mechanistic effects by which radiofrequency exposure might lead to cancer.Scientific evidence―human studies of cell phone use

    The Interphone Study, a 13-country consortium of case-control studies of cell phone use and risk for malignant or benign brain tumors, is the largest study of long-term cell phone use. Interphone researchers found that cell phone users had reduced risks for glioma and meningioma overall, and they found no evidence of increasing risk with progressively increasing number of calls, longer call time, or years since beginning cell phone use. The small proportion of study participants who reported spending the most total time on cell phone calls (13 percent of people with brain tumors and 8 percent of those without tumors) experienced a statistically significant, albeit modest, increase in risk of glioma.

    There was some indication that the association with glioma among heaviest users of cell phones was more apparent for phone use on the same side of the head as the tumor, but the authors noted that this could have been due to reporting bias. However, if the relationship were causal, it would translate into an increase from the current age-adjusted incidence rate of brain cancer in the United States of about 6.5 cases per 100,000 people to about 9 cases per 100,000. The Interphone researchers considered this finding inconclusive due to implausible levels of use reported by a subset of the heaviest users. Interphone was coordinated by the International Agency for Research on Cancer (IARC).

    Interphone and other case-control studies of acoustic neuroma. The individual studies of cell phone use and risk of acoustic neuroma are based on small numbers of cases. A pooled analysis of data from Interphone investigators from Denmark, Finland, Norway, Sweden, and the United Kingdom did not find relationships between the risk of acoustic neuroma and the duration of cell phone use, cumulative hours of use, or number of calls; however, the risk of a tumor on the same side of the head as the reported phone use was higher among persons who had used a cell phone for 10 years or more. A Swedish case-control study reported similar findings, but a Danish case-control study showed no increased risk in long-term (10 years or more) cell phone users compared with short-term users, and no increase in the incidence of tumors on the side of the head where the phone was usually held. Patients with a tumor on one side of their head might be more likely to report phone use on that side.

    A cohort study in Denmark attempted to avoid some of the biases associated with case-control studies (see below in Question 4) by linking billing information from over 420,000 cell phone subscribers with brain tumor incidence data from the Danish Cancer Registry. Cell phone use was not associated with glioma, meningioma, or acoustic neuroma, even among persons who had been subscribers for 10 or more years. Although this approach does not provide direct data on cell phone frequency or duration of use, and the subscriber may not be the primary user of the phone, the prospective cohort design precludes the need to rely on recall of past cell phone use.

    Most earlier case-control studies in the United States, Europe, and Japan generally did not demonstrate associations of cell phone use with glioma or meningioma, except for case-control studies in areas of Sweden which found statistically significant associations with cumulative use and latency that were highest in subjects with first use before the age of 20. See Question 4 for more information about why these studies may differ.

    Case-control studies of tumors other than brain and central nervous system. There are very few human studies of the possible relationship between cell phone use and tumors other than those of the brain and central nervous system, such as tumors of the parotid gland.

    Cancer trends over time. Incidence data from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute have shown no increase in the age-adjusted incidence of brain and other nervous system cancers between 1987 and 2007, despite the dramatic increase in the use of cell phones. Similarly, incidence data from Denmark, Finland, Norway, and Sweden for the period 1974-2003 revealed no increase in age-adjusted incidence of brain and other central nervous system tumors. If cell phones play a role in the risk of brain cancer, one might expect to see an increase in rates because average monthly hours of cell phone use have increased regularly for the past two decades in the United States and Nordic countries.

    Scientific evidence―human studies of cancer risks associated with other sources of radiofrequency

    Studies of workers exposed to radiofrequency have shown no evidence of increased risk of brain tumors among U.S. Navy electronics technicians, aviation technicians or fire control technicians, those working in an electromagnetic pulse test program, plastic-ware workers, cellular phone manufacturing workers, or Navy personnel with a high probability of exposure to radar.

    Scientific evidence―animal and mechanistic studies

    Scientists have not yet identified the mechanism by which radiofrequency energy might cause cancer. Exposure to radiofrequency energy does not appear to result in damage to DNA. To date, studies of rodents exposed to radiofrequency radiation provide no clear or consistent evidence that this type of radiation causes cancer, nor that it enhances the carcinogenicity of known chemical carcinogens.

    The National Institute of Environmental Health Sciences, a part of NIH, is carrying out a study of risks related to exposure to radiofrequency radiation (the type used in cell phones) in highly specialized labs that can specify and control sources of radiation and measure their effects on rodents.

    Conclusions of Expert Organizations

    The International Agency for Research on Cancer (IARC), a component of the World Health Organization, has recently classified radiofrequency fields as “possibly carcinogenic to humans,” based on limited evidence from human studies, limited evidence from studies of radiofrequency and carcinogenicity in rodents, and weak mechanistic evidence (from studies of genotoxicity, effects on immune function, gene and protein expression, cell signaling, oxidative stress, and apoptosis, along with studies of the possible effects of radiofrequency energy on the blood-brain barrier).

    The American Cancer Society states that most studies to date have not found an association between cell phone use and development of tumors. However, results from these studies have been limited by the length of follow-up, changing patterns of cell phone usage and technology, lack of study of children, and methods for measuring cell phone use. Possible cancer risks of cell phone exposure should continue to be evaluated using high-quality methodological approaches, particularly in relation to use in childhood and adolescence and longer-term use.

    The National Institute of Environmental Health Sciences (NIEHS) is currently conducting the largest laboratory rodent study to date on radiofrequency energy exposures in rodents; the studies are designed to mimic human exposure and are based on the frequencies and modulations of cell phones currently in use in the United States. NIEHS states that the weight of the current scientific evidence has not conclusively linked cell phones with any adverse health problems, but more research is needed.

    The U.S. Food and Drug Administration, which is responsible for regulating the safety of machines and devices that emit radiation (including cell phones), notes that studies reporting biological changes associated with radiofrequency energy have failed to be replicated and that the majority of human epidemiologic studies have failed to show an association between exposure to radiofrequency from cell phones and health problems.

    The U.S. Centers for Disease Control and Prevention states that although some studies have raised concerns, the scientific research as a whole does not support a significant association between cell phone use and health effects.

    The Federal Communications Commission concludes that there is no scientific evidence to prove that wireless phone usage can lead to cancer or a variety of other health problems, including headaches, dizziness or memory loss. 

  4. Why are there inconsistencies among the studies?Even among studies that show an association between cell phone use and cancer, the results are conflicting. Studies in Sweden have reported elevated risks at usage levels where Interphone finds no association. There are several possible reasons for discrepancies between some studies:
    • Information about cell phone use, including the frequency of use and the duration of calls, has largely been assessed through questionnaires. The completeness and accuracy of the data collected during such interviews depend on the memory of the responding individuals. In case-control studies, individuals with brain tumors may remember cell phone use differently from healthy individuals, which can result in a problem known as recall bias.
    • In the Interphone study, cell phone use among people who developed a brain tumor was more likely to be reported on the same side of the head as the brain tumor. Both low users and high users of cell phones reported this pattern, making the predominance of same-side-of-the-head use less likely to be causal; instead, the pattern may reflect over-reporting. Further, there’s no reason to expect reduced risk of tumor occurrence among those using cell phones on the opposite side of the head, as reported in that study.
    • Gliomas are particularly difficult to study in large part because of high mortality and short survival. Patients who survive initial treatment are often impaired, which may affect their responses. Furthermore, for cases who have died, next-of-kin are often less familiar with the cell phone use patterns of the affected family member and may not accurately describe patterns of use to an interviewer.
    • Epidemiologic studies of cell phone use and brain cancer risk lack verifiable data about cumulative exposure over time (the total amount of radiofrequency energy individuals have encountered). These studies are also vulnerable to errors in the reporting of exposure by study participants.
    • Study participation rates are frequently different between those with cancer and those without cancer in brain tumor studies, a problem known as participation bias. Some studies have indicated greater participation by individuals diagnosed with brain tumors compared with control subjects, and participation rates may be related to cell phone use. For example, the Interphone study reported participation rates of 78 percent for meningioma cases (range 56 to 92 percent for the individual studies), 64 percent (range 36 to 92 percent) for the glioma cases, and 53 percent (range 42 to 74 percent) for controls. The Swedish studies reported participation rates of 85 percent in cases and 84 percent in controls.
    • The interval between exposure to a carcinogen and the clinical onset of a tumor may be many years or decades. Memory of events that occurred years to decades ago may be problematic. In case-control studies, it is not possible to prospectively monitor cases and controls for the length of time it might take for brain tumors to develop.
    • Cellular technology continues to change. Although older studies evaluated radiofrequency energy exposure from analog telephones, most cell phones today use digital technology, which operates at a different frequency and a lower power level than analog phones.
    • The use of “hands-free” wireless technology is increasing and may alter exposure.

    Investigators from the Interphone study looked at potential sources of bias that could affect the conclusions of epidemiologic studies. They found lower frequency of regular cell phone use among control subjects than among patients with brain tumors, and they quantified how this difference might affect the study’s results. They found moderate to high correlation between use that was measured (with special software-equipped phones) and recalled use. Light users were more likely to underestimate their use, and heavy users were more likely to overestimate their use and length of calls. A comparison of cell phone subscriber data with reported cell phone use from interviews revealed that both brain tumor patients and control subjects underestimated the number of calls and overestimated call duration. 

  5. What studies are still under way that will help further our understanding?A large, prospective cohort study of cell phone use and its possible long-term health effects was launched in Europe in March 2010. This study, known as COSMOS, will enroll approximately 250,000 cell phone users ages 18 or older and will follow them for 20 to 30 years. Participants in COSMOS will complete a questionnaire about their health, lifestyle, and current and past cell phone use. This information will be supplemented with information from health records and cell phone records.The challenge of such an ambitious study is to maintain the cohort over many decades. Researchers will need to determine if those participants who leave the study are somehow different from those who remain throughout the follow-up period.

    Although recall bias is minimized in studies that also link to cell phone records, such studies face other problems. For example, it is impossible to know who is using the cell phone or whether that individual may also place calls using other cell phones. To a lesser extent, it is not clear if multiple users of a single phone are represented on one bill. 

  6. Do children have a higher risk of developing cancer due to cell phone use than adults?There are currently no data on cell phone use and risk of cancer in children. None of the published studies to date have included children.  Cell phone use by children and adolescents is increasing rapidly, and they are likely to accumulate many years of exposure during their lives. In addition, children may be at greater risk because their nervous systems are still developing at the time of exposure. A large case-control study of childhood brain cancer in several northern European countries is in progress. Researchers from the Centre for Research in Environmental Epidemiology in Spain are also conducting an international study—Mobi-Kids—to evaluate risk from new communications technologies (including cell phones) and other environmental factors in young people ages 10 to 24. 
  7. What can cell phone users do to reduce their exposure to radiofrequency energy?The Food and Drug Administration and the Federal Communications Commission have suggested some steps that cell phone users can take to reduce their exposure:
    • Reserve the use of cell phones for shorter conversations or for times when a conventional phone is not available.
    • Switch to a type of cell phone with a hands-free device that will place more distance between the phone and the head of the user.

    Hands-free kits reduce the amount of radiofrequency energy exposure to the head because the antenna, which is the source of energy, is not placed against the head. 

  8. Where can I find more information about radiofrequency energy from my cell phone?The Federal Communications Commission provides information about the specific absorption rate (SAR) of many recent cell phones. The SAR corresponds to the relative amount of radiofrequency energy absorbed into the head of a cell phone user. Consumers can access this information using the phone’s FCC ID number, which is usually located on the case of the phone, and the FCC’s ID search form. 
  9. What are other sources of radiofrequency energy?The most common use of radiofrequency energy is for telecommunications. In the United States, cell phones currently operate in a frequency range of about 1,800 to 2,200 megahertz (MHz). In this range, the electromagnetic radiation produced is in the form of non-ionizing radiofrequency energy. Cordless phones (phones that have a base unit connected to the telephone wiring in a house) often operate at radio frequencies similar to those of cell phones; however, since cordless phones have a limited range and require a nearby base, their signals are generally much less powerful than those of cell phones. Among other radiofrequency energy sources, AM/FM radios and VHF/UHF televisions operate at lower radio frequencies than cell phones, whereas sources such as radar, satellite stations, magnetic resonance imaging (MRI) devices, industrial equipment, and microwave ovens operate at somewhat higher radio frequencies. 
  10. How common is brain cancer? Has the incidence of brain cancer changed over time?Brain cancer incidence and mortality (death) rates have changed little in the past decade. In the United States, 22,020 new diagnoses and 13,140 deaths from brain cancer were estimated for 2010.The 5-year survival rate for brain cancers diagnosed from 2001 to 2007 was 33.4 percent. This means that 33.4 out of every 100 persons diagnosed with brain cancer today will survive at least 5 years.

    The risk of developing brain cancer increases with age. Between 2000 and 2008, there were fewer than 5 brain cancer cases for every 100,000 people in the United States under age 65, compared with approximately 19 cases for every 100,000 people in the United States who were ages 65 or older.

Selected References 

  1. Ahlbom A, Feychting M, Green A, et al. Epidemiologic evidence on mobile phones and tumor risk: a review. Epidemiology 2009; 20(5):639–652. [PubMed Abstract] 
  2. Ahlbom A, Green A, Kheifets L, Savitz D, Swerdlow A. Epidemiology of health effects on radiofrequency exposure. Environmental Health Perspectives 2004; 112(17):1741–1754. [PubMed Abstract] 
  3. American Cancer Society (2011). Learn About Cancer―Cellular Phones. Retrieved June 16, 2011. 
  4. Baan R, Grosse Y, Lauby-Secretan B, et al., on behalf of the World Health Organization International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of radiofrequency electromagnetic fields. The Lancet Oncology. Published early online June 22, 2011. DOI:10.1016/S1470-2045(11)70147-4. 
  5. Cardis E, Richardson L, Deltour I, et al. The INTERPHONE study: design, epidemiological methods, and description of the study population. European Journal of Epidemiology 2007; 22(9):647–664. [PubMed Abstract] 
  6. Centers for Disease Control and Prevention (2011). Frequently Asked Questions About Cell Phones. Atlanta, GA. Retrieved on June 16, 2011. 
  7. Christensen HC, Schuz J, Kosteljanetz M, et al. Cellular telephones and risk for brain tumors: a population-based, incident case-control study. Neurology 2005; 64(7):1189–1195. [PubMed Abstract] 
  8. Christensen HC, Schuz J, Kosteljanetz M, et al. Cellular telephone use and risk of acoustic neuroma. American Journal of Epidemiology 2004; 159(3):277–283. [PubMed Abstract] 
  9. Deltour I, Johansen C, Auvinen A, et al. Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden, 1974–2003. Journal of the National Cancer Institute 2009; 101(24):1721–1724. [PubMed Abstract] 
  10. Hardell L, Carlberg M, Hansson Mild K. Pooled analysis of case-control studies on malignant brain tumours and the use of mobile and cordless phones including living and deceased subjects. International Journal of Oncology 2011; 38(5):1465–1474. [PubMed Abstract] 
  11. Hardell L, Carlberg M. Mobile phones, cordless phones and the risk for brain tumours. International Journal of Oncology 2009; 35:5–17. [PubMed Abstract] 
  12. Hepworth SJ, Schoemaker MJ, Muir KR, et al. Mobile phone use and risk of glioma in adults: case-control study. British Medical Journal 2006; 332(7546):883–887. [PubMed Abstract] 
  13. Hirose H, Suhara T, Kaji N, et al. Mobile phone base station does not affect neoplastic transformation in BALB/3T3 cells. Bioelectromagnetics 2008; 29(1):55–64. [PubMed Abstract] 
  14. Hours M, Bernard M, Montestrucq L, et al. [Cell phones and risk of brain and acoustic nerve tumours: the French INTERPHONE case-control study.] Revue d’Epidemiologie et de Sante Publique 2007; 55(5):321–332. [PubMed Abstract] 
  15. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2008. Bethesda, MD: National Cancer Institute. 
  16. Inskip PD, Tarone RE, Hatch EE, et al. Cellular-telephone use and brain tumors. New England Journal of Medicine 2001; 344(2):79–86. [PubMed Abstract] 
  17. International Agency for Research on Cancer (2008). INTERPHONE Study: Latest results update—8 October 2008. Lyon, France. Retrieved June 16, 2011. 
  18. Johansen C, Boice Jr. JD, McLaughlin JK, Olsen JH. Cellular telephones and cancer: a nationwide cohort study in Denmark. Journal of the National Cancer Institute 2001; 93(3):203–207. [PubMed Abstract] 
  19. Klaeboe L, Blaasaas KG, Tynes T. Use of mobile phones in Norway and risk of intracranial tumours. European Journal of Cancer Prevention 2007; 16(2):158–164. [PubMed Abstract] 
  20. Lahkola A, Salminen T, Raitanen J, et al. Meningioma and mobile phone use—a collaborative case-control study in five North European countries. International Journal of Epidemiology 2008; 37(6):1304–1313. [PubMed Abstract] 
  21. Lahkola A, Auvinen A, Raitanen J, et al. Mobile phone use and risk of glioma in five North European countries. International Journal of Cancer 2007; 120(8):1769–1775. [PubMed Abstract] 
  22. Lahkola A, Salminen T, Auvinen A. Selection bias due to differential participation in a case-control study of mobile phone use and brain tumors. Annals of Epidemiology 2005; 15(5):321–325. [PubMed Abstract] 
  23. Linet MS, Taggart T, Severson RK, et al. Cellular telephones and non-Hodgkin lymphoma. International Journal of Cancer 2006; 119(10):2382–2388. [PubMed Abstract] 
  24. Lönn S, Ahlbom A, Christensen HC, et al. Mobile phone use and risk of parotid gland tumor. American Journal of Epidemiology 2006; 164(7):637–643. [PubMed Abstract] 
  25. Lönn S, Ahlbom A, Hall P, Feychting M, Swedish Interphone Study Group. Long-term mobile phone use and brain tumor risk. American Journal of Epidemiology 2005; 161(6):526–535. [PubMed Abstract] 
  26. Lönn S, Ahlbom A, Hall P, Feychting M. Mobile phone use and the risk of acoustic neuroma. Epidemiology 2004; 15(6):653–659. [PubMed Abstract] 
  27. Muscat JE, Malkin MG, Thompson S, et al. Handheld cellular telephone use and risk of brain cancer. Journal of the American Medical Association 2000; 284(23):3001–3007. [PubMed Abstract] 
  28. National Institute of Environmental Health Sciences (2011). Cell Phones. Research Triangle Park, NC. Retrieved June 16, 2011. 
  29. Oberto G, Rolfo K, Yu P, et al. Carcinogenicity study of 217 Hz pulsed 900 MHz electromagnetic fields in Pim1 transgenic mice. Radiation Research 2007; 168(3):316–326. [PubMed Abstract] 
  30. Sadetzki S, Chetrit A, Jarus-Hakak A, et al. Cellular phone use and risk of benign and malignant parotid gland tumors—a nationwide case-control study. American Journal of Epidemiology 2008; 167(4):457–467. [PubMed Abstract] 
  31. Schoemaker MJ, Swerdlow AJ, Ahlbom A, et al. Mobile phone use and risk of acoustic neuroma: results of the Interphone case-control study in five North European countries. British Journal of Cancer 2005; 93(7):842–848. [PubMed Abstract] 
  32. Schuz J, Jacobsen R, Olsen JH, et al. Cellular telephone use and cancer risk: update of a nationwide Danish cohort. Journal of the National Cancer Institute 2006; 98(23):1707–1713. [PubMed Abstract] 
  33. Stang A, Schmidt-Pokrzywniak A, Lash TL, et al. Mobile phone use and risk of uveal melanoma: results of the risk factors for uveal melanoma case-control study. Journal of the National Cancer Institute 2009; 101(2):120–123. [PubMed Abstract] 
  34. Takebayashi T, Varsier N, Kikuchi Y, et al. Mobile phone use, exposure to radiofrequency electromagnetic field, and brain tumour: a case-control study. British Journal of Cancer 2008; 98(3):652–659. [PubMed Abstract] 
  35. The INTERPHONE Study Group. Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. International Journal of Epidemiology 2010; 39(3):675–694. [PubMed Abstract] 
  36. U.S. Federal Communications Commission (2009). Wireless. Washington, D.C. Retrieved June 16, 2011. 
  37. U.S. Federal Communications Commission (2009). Cellular Telephone Specific Absorption Rate (SAR). Washington, D.C. Retrieved June 16, 2011. 
  38. U.S. Food and Drug Administration (2010). Radiation Emitting Products―Cell Phones. Silver Spring, MD. Retrieved June 16, 2011. 
  39. U.S. Food and Drug Administration (2009). Radiation-Emitting Products: Reducing Exposure: Hands-free Kits and Other Accessories. Silver Spring, MD. Retrieved June 16, 2011. 
  40. Verschaeve L, Juutilainen J, Lagrove I, et al. In vitro an din vivo genotoxicity of radiofrequency fields. Mutation Research 2010; 705(3):252–268. [PubMed Abstract] 
  41. Vijayalaxmi, Prihoda TJ. Genetic damage in mammalian somatic cells exposed to radiofrequency radiation: a meta-analysis of data from 63 publications (1990–2005). Radiation Research 2008; 169(5):561–574. [PubMed Abstract] 
  42. Vrijheid M, Richardson L, Armstrong BK, et al. Quantifiying the impact of selection bias caused by nonparticipation in a case-control study of mobile phone use. Annals of Epidemiology 2009; 19(1):33–41. [PubMed Abstract] 
  43. Vrijheid M, Armstrong BK, Bédard D, et al. Recall bias in the assessment of exposure to mobile phones. Journal of Exposure Science and Environmental Epidemiology 2009; 19(4):369–381. [PubMed Abstract] 
  44. Vrijheid M, Deltour I, Krewski D, Sanchez M, Cardis E. The effects of recall errors and of selection bias in epidemiologic studies of mobile phone use and cancer risk. Journal of Exposure Science and Environmental Epidemiology 2006; 16(4):371–384. [PubMed Abstract] 
  45. Vrijheid M, Cardis E, Armstrong BK, et al. Validation of short term recall of mobile phone use for the Interphone study. Occupational and Environmental Medicine 2006; 63(4):237–243. [PubMed Abstract]
  46. Zook BC, Simmens SJ. The effects of pulsed 860 MHz radiofrequency radiation on the promotion of neurogenic tumors in rats. Radiation Research 2006; 165(5):608–615. [PubMed Abstract]

# # #

Related NCI materials and Web pages:

How can we help?

We offer comprehensive research-based information for patients and their families, health professionals, cancer researchers, advocates, and the public.

Leksell Gamma Knife Administrators Meeting

June 23rd, 2011

Paul Loflin, Administrator, Beth Advani, Financial Coordinator, and I recently attended the North America Leksell Gamma Knife Administrators Meeting, sponsored by Elekta, held at the exquisite La Playa Beach & Golf Resort in Naples, Florida. The 4-day meeting provided a forum for the exchange of business and marketing strategies among Gamma Knife centers across the nation. Presentations included topics such as “Anatomy of a Gamma Knife Program for New Administrators”, “Healthcare Reform: How to Understand Upcoming Policy Effrects”, “Radiosurgery Today and Tomorrow”, “Utilization Trends: Current and Future Directions”, “Free and Low Cost Tools for Increasing Your Web Presence”, “Best Business Practices for Coding and Reimbursement”, “Marketing Your Program in a Competetive Landscape”, Case Studies: Focus on the Patient Experience”, and “Gamma Knife Radiosurgery: Current Status and Future Directions”. We appreciated the opportunity to participate in this exciting and educational event.

Lorrie Morris, Business Development Manager

Press Release: SDGKC Treats 500th Patient Afflicted With Trigeminal Neuralgia

January 18th, 2011

Contact: Lorrie Morris                                            For Immediate Release

Tel. 800-924-2662

Cell Phone: 760-445-1740

Email: lorriemorris@sdgkc.com

SAN DIEGO GAMMA KNIFE CENTER TREATS 500th PATIENT

AFFLICTED WITH TRIGEMINAL NEURALGIA

San Diego Gamma Knife Center has just treated its 500th patient diagnosed with Trigeminal Neuralgia (or, Tic Douloureaux).  This extremely painful disorder of the facial nerve is infrequent, but the effects are devastating. Trigeminal Neuralgia originates from one or more branches of the trigeminal nerve that supply sensation to the face; and, is considered one of the most painful conditions known.  Sufferers complain of extreme electrical shock-like pains in the face.  Pain may be triggered by the slightest touch, so eating can be difficult or even impossible.

Among the surgical options for trigeminal neuralgia, Gamma Knife® Radiosurgery is the only non-invasive procedure which produces results comparable to open surgery. Gamma Knife produces an extremely focused center of radiation, fractions of an inch in size, which pinpoints the source of the pain with virtually no side effects. The treatment does not require hospital admission as patients return home just hours after treatment.  An additional benefit of Gamma Knife radiosurgery is that it avoids virtually all of the complications of invasive procedures.

Of the 500 patients treated was the mother of San Diego Gamma Knife Center’s physicist, Dr. Steven Goetsch.  Mrs. Goetsch suffered from trigeminal neuralgia for 16 years with little result from other treatments.  After Gamma Knife treatment in 1999, she spent the last 7 years of her life pain-free and off medications.  She expressed her gratitude to her son for allowing her to spend these years serving others while relieved of pain.

Diana, the sister-in-law of the Center’s Medical Director, Dr. Kenneth Ott, was unable to eat for weeks because of tic pain. She came to the Center from Nebraska for Gamma Knife Radiosurgery. She was unable to eat dinner the night before the non-invasive procedure. Her pain ended the afternoon of the procedure, and she enjoyed an excellent dinner that night (prepared by Dr. Ott) and she remains pain-free to date.

According to Dr. Ott, “Gamma Knife is valuable because it’s noninvasive. There’s no incision, no pain, no lengthy recovery, no hair loss or scarring, no general anesthesia, and a rapid return to normal activities.”

The 500 patients treated for trigeminal neuralgia during the past 15 years add to the more than 3,500 patients treated at the San Diego Gamma Knife Center for various problems, including benign and malignant brain tumors.  The Center has the most extensive radiosurgery experience for treating brain tumors in Southern California and one of the leading centers in the world for the treatment of trigeminal neuralgia.

San Diego Gamma Knife Center was opened as a Neurosurgical Center of Excellence in 1994; and, operates as part of the Neuroscience Department of Scripps Memorial Hospital La Jolla, and Scripps Cancer Center, Stevens Division, who provide diagnosis, treatment and support for a full range of neurological disorders.  More information may be obtained by visiting the website at www.sdgkc.com or calling 800-924-2662.

# # #

If you’d like more information about this topic, or to schedule an interview with Kenneth Ott, M.D., please call Lorrie Morris at 760-445-1740 or send an email to: lorriemorris@sdgkc.com

Response to NYTimes article, A Pinpoint Beam Strays Invisibly, Harming Instead of Healing

January 9th, 2011

Re: NY Times article: http://www.nytimes.com/2010/12/29/health/29radiation.html

Response from Kenneth Ott, MD, and David Hodgens, MD

January 4, 2011
Editor
New York Times
Dear Sirs:

Thank you for the excellent article pointing out the risks associated with radiosurgery performed on equipment that is not dedicated to that purpose, and that is often a hybrid created with one company’s hardware driven by another company’s software, and then purchased by administrators that want to compete on the cheap.

As the Medical Directors of the San Diego Gamma Knife Center, the potential for exactly the type of complication described in the article is what compelled us, in 1994, to demand a treatment unit dedicated solely to brain radiosurgery, and we have operated a modern Gamma Knife Center in the San Diego area ever since, performing more than 3,000 procedures.

Radiosurgery is strong medicine.  We have seen it do wondrous good, but it has the potential to do life and limb threatening harm.  It is scalpel in the hands of some, or a dangerous, sharp knife in the hands of others.  As this technique has evolved outside the brain over the past twenty-five years, we have continued to advocate the use of dedicated equipment, and thus use a CyberKnife unit for extra-cranial radiosurgery.  With equipment, staff, and physicians dedicated to doing only one thing, the risk of human error, lapse of oversight, or incompatible computer technologies is either eliminated or greatly reduced, and the treatment is inherently safer, and in our opinion, more effective for the patient.

Your article illuminates a real problem in our field, and should push our colleagues in radiosurgery (before they are pushed by regulatory bodies) to have second thoughts about performing radiosurgery using what amount to modified, hybridized linear accelerators, and to consider doing what is ultimately best for patients—the utilization of dedicated radiosurgical devices like the Gamma Knife and CyberKnife.

Yours Sincerely,

Kenneth H. Ott M.D.      David W. Hodgens, M.D.

December 28, 2010

A Pinpoint Beam Strays Invisibly, Harming Instead of Healing

By WALT BOGDANICH and KRISTINA REBELO

The initial accident report offered few details, except to say that an unidentified hospital had administered radiation overdoses to three patients during identical medical procedures.

It was not until many months later that the full import of what had happened in the hospital last year began to surface in urgent nationwide warnings, which advised doctors to be extra vigilant when using a particular device that delivers high-intensity, pinpoint radiation to vulnerable parts of the body.

Marci Faber was one of the three patients. She had gone to Evanston Hospital in Illinois seeking treatment for pain emanating from a nerve deep inside her head. Today, she is in a nursing home, nearly comatose, unable to speak, eat or walk, leaving her husband to care for their three young daughters.

Two other patients were overdosed before the hospital realized that the device, a linear accelerator, had inexplicably allowed radiation to spill outside a heavy metal cone attachment that was supposed to channel the beam to a specific spot in the brain. One month later, the same accident happened at another hospital.

The treatment Ms. Faber received, stereotactic radiosurgery, or SRS, is one of the fastest-growing radiation therapies, a technological innovation designed to target tiny tumors and other anomalies affecting the brain or spinal cord, while minimizing damage to surrounding tissue.

Because the radiation is so concentrated and intense, accuracy is especially important. Yet, according to records and interviews, the SRS unit at Evanston lacked certain safety features, including those that might have prevented radiation from leaking outside the cone.

The mistakes in Evanston involve linear accelerators — commonly used for standard radiation therapy — that were redesigned by the manufacturer, Varian Medical Systems, so they could also perform SRS. As the devices became more versatile and complex, problems arose when vital electronic components could not communicate with one another.

In the last five years, SRS systems made by Varian and its frequent German partner, Brainlab, have figured in scores of errors and overdoses, The New York Times has found. Some mistakes were caused by operator error. In Missouri, for example, 76 patients were overradiated because a medical physicist did not realize that the smaller radiation beam used in radiosurgery had to be calibrated differently than the larger beam used for more traditional radiation therapy.

Medical physicists say there is nothing inherently wrong with linear accelerators that deliver general radiation therapy, as well as SRS. And, they say, the overdoses might have been caught had users followed a more rigorous system of checks and double-checks.

“Tens of thousands of patients have been treated with protocols properly followed and no mistakes were made,” said Dr. Frank J. Bova, a medical physicist in Gainesville, Fla., and a pioneer in developing and enhancing the accuracy of SRS. “It has changed many difficult procedures, ones with high surgical risk, into one-day outpatient procedures.”

But radiation safety experts say the retrofitted devices made up of different companies’ products present a special challenge.

Dr. Howard I. Amols, chief of clinical physics at Memorial Sloan-Kettering Cancer Center in New York, said some problems appeared to be “a combination of user error, coupled with neither the manufacturers nor the F.D.A. being able to anticipate a potential safety flaw in a ‘mix and match’ treatment delivery system.”

Dr. William David Bloomer, chairman of radiation medicine at Evanston Hospital, said the mistakes happened even though medical personnel there had followed the manufacturer’s instructions. “We rely on them to make sure the medical devices are safe,” he said.

Varian, the world’s leading manufacturer of linear accelerators, declined to be interviewed, but said in a statement that it has “deep concern” for accident victims and their families. “Our products include many built-in safety features, and we work continually to make them even safer,” Varian said.

Brainlab denied any role in the accidents.

The accidents highlight shortcomings in the regulation of medical radiation.

Despite their complexity, the multipurpose devices are less regulated than their more simply designed competitor, the Gamma Knife, a device engineered specifically for stereotactic radiosurgery.

Linear accelerators, which generate radiation without using radioactive material, are overseen by the Food and Drug Administration, while the Gamma Knife is regulated by the Nuclear Regulatory Commission because it uses a radioactive isotope. The nuclear commission has more authority to investigate and publicize radiation errors.

The F.D.A. approved the retrofitted linear accelerators with little review on the grounds that they were mere extensions of existing technology.

But since there is no requirement that all mistakes involving linear accelerators be reported to a central database, getting a handle on how often SRS errors occur is difficult. “Everybody says these are isolated incidents,” Dr. Bloomer said, “until you find out that maybe they are not so isolated.”

Seeking Respite From Pain

Before Marci Faber became a nursing home invalid at age 50, she had been leading a rich, full life. She loved musicals, country music and anything to do with her three daughters. When a mother was needed to oversee the sale of Girl Scout cookies, Ms. Faber was there.

“We go into a room and people really didn’t care so much about me — Marci was definitely the person that people gravitated to,” said Richard Faber, her husband. “She was gregarious, had a great smile. Her eyes light up the room.”

Last March, Ms. Faber sought treatment for trigeminal neuralgia, a non-life-threatening condition that produces facial pain. While Ms. Faber’s pain was intermittent, some cases become severe.

“It’s unimaginably bad and can drive some people to suicide,” said Dr. Daniel Yoshor, chief of neurosurgery at St. Luke’s Episcopal Hospital in Houston. “It’s an awful, awful thing and the cause of it is not very well understood.”

What is known is that the pain emanates from the tiny trigeminal nerve at the base of the brain. And stereotactic radiosurgery is one of the most effective methods of eliminating the source of the pain.

But treating trigeminal neuralgia “is probably the most technically demanding” form of radiosurgery, said Dr. Bova. “You are literally giving doses that are very, very high,” he said, “and the machine has to be able to deliver the dose to the trigeminal nerve and stay off the brain stem, which is immediately adjacent to it.”

Standard radiation therapy can involve dozens of treatments at lower doses, so one incorrect treatment might not cause much damage. But with SRS, there is often just a single potent dose requiring scalpel-like accuracy.

“It requires a little different mindset than when you are actually saying, I will give a little dose today, a little dose tomorrow and I will check it later,” Dr. Bova said. “This has to be checked the first time you do it because there is not a second day.”

For years, the Gamma Knife provided the necessary power and accuracy to accomplish its goal.

But many institutions could not afford it; the device costs upwards of $3 million and requires its own room, and treatments take longer. There is also the added difficulty of handling and replacing radioactive material.

“It doesn’t pay to have a Gamma Knife unless you have a large number of patients,” said Dr. Amols.

By using linear accelerators retrofitted with cone attachments, hospitals expanded their pool of patients without having to buy an extra unit.

Radiosurgery appeals to patients because it is an alternative to surgery and can be performed as an outpatient procedure, often in a single day. In recent years, the use of these small beam treatments has soared, as doctors have begun using them on parts of the body other than the brain and spine.

When Ms. Faber entered Evanston Hospital in March 2009, she had every reason to believe that her treatment would put an end to her pain. Indeed, when she left the hospital her trigeminal nerve was no longer an issue.

Little Problems Get Bigger

At first, Ms. Faber had no reason to be especially concerned. After her procedure, she experienced some vomiting, burning in her throat, and even a little weight loss. Swatches of hair began to fall out.

Still, the Fabers did not connect any of this to her radiation treatment.

But weeks later, as the hospital was on the verge of overradiating a fourth radiosurgery patient, its medical physicist caught the problem. He fixed it, and the patient received the correct dose.

But the hospital temporarily shut down its stereotactic radiosurgery program and began to investigate. What it found was deeply disturbing: three patients, including Ms. Faber, had been overradiated around the same time. All the victims were notified.

Evanston Hospital declined to discuss specific cases on privacy grounds, but a brief report sent to the F.D.A. in 2009 said one patient had been hospitalized three weeks after treatment with an irregular heartbeat, weakness, and changes in mental status; another was hospitalized for four days because of nausea, vomiting and dehydration; and the third, apparently Ms. Faber, was said to have experienced hair loss.

But about a year after her treatment, Mr. Faber said, his wife began losing her balance, falling occasionally and having memory problems. “I was sick to my stomach — scared,” he said.

Jordan Kagan, a family friend, said that when Ms. Faber attended his daughter’s bat mitzvah in April, she was mentally coherent but physically diminished.

Then, in what seemed like a blink of an eye, she disintegrated. “Four weeks later, she was like a vegetable,” Mr. Kagan said. “It was mind-boggling to see one person who was not elderly deteriorate that quickly.”

Now, she can only blink her eyes and lightly squeeze her husband’s hand. “It is very hard on the kids,” Mr. Faber said. “It has been hard on me but really nothing compared to what Marci is going through.”

Doctors who deal with her type of radiation injury say the prognosis for any meaningful recovery is poor.

At the hospital, officials had been scrambling to figure out what went wrong. While the software that drives the linear accelerator is complex, the mechanics of how the overdoses occurred is strikingly simple.

Linear accelerators can be adapted to perform stereotactic radiosurgery in two ways: with small computer-controlled metal leaves that shape the beam, or with a cone attached to the machine’s opening through which radiation is delivered. That opening is made smaller or larger by moving four heavy metal “jaws” that shape the beam into a square. When a cone attachment is used, the square beam must fit entirely within the circumference of the cone. If the square is slightly larger than the cone, radiation will leak out through the four corners of the jaws and irradiate healthy tissue. In the Evanston accidents, records show, the beam was four times too large.

Operators could not see this incorrect setting directly because a metal tray on which the cone is mounted hides the jaws, though the settings should have been displayed on a computer screen, according to people who have worked with this device. The mount also blocks a light field that could have shown where the radiation was to hit the patient.

But while the mount blocks light, it does not block radiation, which in the case of Ms. Faber and other Evanston patients went into healthy brain cells.

Determining that the jaws had been set wrong was the easy part. Then the hospital had to figure out how and why.

A Failure to Communicate

Precisely why the jaws were open so wide is still in dispute. There is no indication that the State of Illinois or the F.D.A. has investigated the accident. No lawsuits have been filed. And Varian has declined to answer questions.

But public records and interviews with doctors and others familiar with Varian’s equipment point to a complicated matrix of computer systems and communication flaws that made such an accident more likely to happen.

That system is supposed to work this way: A treatment plan is developed on one computer, then transferred into another software system that, among other things, verifies that the treatment plan matches the doctor’s prescription. The data is then sent to a third computer that controls the linear accelerator.

Several months after the Evanston accidents, Brainlab reminded customers to verify the correct jaw setting, specifically citing the possibility that treatment information could be altered as it passed “through a chain of devices.”

Evanston Hospital had earlier encountered its own communication glitches after upgrading Varian software in December 2008. As a result, medical personnel had to load patient information onto a USB flash drive and walk it from one computer to another.

Then, three months ago, concerned that radiation might leak outside the cone, Varian warned customers that its software did not recognize cone attachments on the type of linear accelerator involved in the Evanston accidents.

To work around that problem hospitals needed to, as one medical physicist put it, essentially trick the machine into thinking it was using a different attachment, which it did recognize. To do that, users had to enter additional data into the SRS system.

Similar communication problems affected three other Varian brands of linear accelerators.

“If you weren’t careful, you could give the wrong treatment,” said Dr. Subhash C. Sharma, chief physicist at Parkview Comprehensive Cancer Center in Fort Wayne, Ind.

Last year, Varian promised to devise, among other things, a decidedly low-tech solution: a decal to stick on the machines, warning operators to be extra careful in setting the radiation field.

Dr. Bloomer, the radiation oncologist at Evanston Hospital, said the manufacturer had not answered the hospital’s questions about why the overdoses occurred there. “We haven’t gotten an adequate response,” he said.

Dr. Amols, the Sloan Kettering physicist, said he believed several factors could have contributed to the accidents.

“Arguably, the physicist or radiation therapist should have noticed that there was a mismatch,” Dr. Amols said, “and arguably there should be stricter laws regulating the ‘mixing and matching’ of complex medical equipment from different manufacturers. But at present there’s no legal requirement for different companies to make equipment integration transparent to the end user — i.e., the hospitals.”

After the accidents at Evanston, Brainlab and Varian this year released a software fix that will restrict the jaw size, so similar accidents will not occur, said David Brett, a Brainlab official. So far, 75 percent of the affected machines have incorporated the fix, the company said.

Dozens Are Overradiated

While Evanston and its suppliers were dealing with the fallout of the overdose cases there, a different problem involving the retrofitted linear accelerators had been unfolding at CoxHealth, a hospital in Springfield, Mo.

Earlier this year, CoxHealth announced that it had overradiated 76 patients, most of whom had brain cancer, during SRS treatments. The overdoses had continued for five years because the hospital did not realize that its radiation therapy equipment had been set up incorrectly.

The hospital’s medical physicist, who was apparently accustomed to calibrating larger radiation beams, did not realize that smaller beams needed to be handled differently, radiation experts say.

A hospital spokesman said the physicist used the wrong calibration tool to set up the machine, causing the overdoses.

“They were supposed to have switched over to a smaller detector,” said Dr. Brad Bradshaw, a lawyer, who represents many of the overdosed patients. “The larger detector gave them a false reading.”

Terri Anderson, 54, was overradiated at Cox last year while undergoing SRS treatment for a benign tumor. After her treatments, she began experiencing facial spasms. “I started having 12 to 14 of those a day,” Ms. Anderson said. She says she also developed balance and memory problems.

Dr. Bradshaw, who represents Ms. Anderson, said parts of her brain had received overdoses ranging from 25 percent to 100 percent.

A similar calibration problem involving a Brainlab and Varian unit was discovered in April 2007 at a hospital in Toulouse, France, where overdoses — smaller than those in Missouri — had occurred for a year, affecting 145 patients. These SRS treatments used tiny metal leaves to shape the beam.

“There were strong similarities between what happened in Missouri and what happened in Toulouse,” said Dr. Ola Holmberg, who heads the radiation protection unit for patients at the International Atomic Energy Agency.

But without a requirement that accidents and near-misses be reported, other hospitals cannot learn from these mistakes, Dr. Holmberg said.

“There is no effective way now of sharing the information or learning in a systematic way,” Dr. Holmberg said. “If something happens, such as Evanston, I would have wanted to know about it at the time.”

That point was echoed by Dr. Benjamin Movsas, chairman of the department of radiation oncology at Henry Ford Health System in Detroit. “I was not able to find any information about Evanston,” Dr. Movsas said. “It’s frustrating. We didn’t know there was a problem.”

Earlier this year, the American Society for Radiation Oncology called for the establishment of the nation’s first central database for the reporting of errors involving linear accelerators. So far that hasn’t happened.

“The system does need to change,” Dr. Movsas said. “Reporting needs to be transparent and mandatory.” He added: “We need regulations — that has to happen. It’s better for me and it’s better for my patients.”

Reflections from Bob

June 11th, 2010

Reflections – 1

Reflections – 2

The title of this blog piece happens to be the title of a book by Robert (Bob) Aldersley from Canada.

Periodically, non-reference books and articles make their way to our Center.

They remind us of why we love healthcare and to never forget the human element.

Bob’s book chronicles his journey from diagnosis of a primary brain tumor to date.

We enjoyed this book and give it our highest recommendation.

Our endorsement comes from not the patient perspective but one man’s love of family, friends and life.

Heck, Bob even personalized our copy.

Thank you Bob!

Welcome to San Diego Gamma Knife Center Blog!

March 8th, 2010

Welcome to San Diego Gamma Knife Center! We are located on the campus of Scripps Memorial Hospital in La Jolla, and since 1994 have been a Center of Excellence for the treatment of Brain Tumors, Acoustic Neuroma, Trigeminal Neuralgia and other brain disorders.

Our facilities function as a shared resource for the San Diego neurosurgical and radiation oncology community, and we receive patients from all over the United States and the world. Gamma Knife radiosurgery is one of the most cutting edge methods of treating brain disorders that avoids many of the dangers and discomforts of conventional surgery treatments.

Patients at the San Diego Gamma Knife Center benefit from effective radiosurgery treatments that involve no incisions, no need for general anesthesia and that do not result in any kind of hair loss or scarring. Over 20 years of studies have shown Gamma Knife radiosurgery to deliver superior outcomes with a high degree of safety and efficiency.

The team of experts working at the San Diego Gamma Knife Center comprises a broad range of medical professionals, including radiation oncologists, medical physicists, neurosurgeons and nurses, all of whom work together to provide our patients with careful, individualized care while they undergo treatment. Each case is reviewed closely, and a specialized treatment plan is developed for each individual patient by a multidisciplinary conference of experts.

Currently, Gamma Knife surgery is the only FDA approved method for the treatment of brain metastases, and is considered the “Gold Standard” of radiosurgery procedures. The cutting edge medical technology used at the San Diego Gamma Knife Center was designed by neurosurgeons and dedicated specifically to the treatment of brain disorders.

The success we have had since the San Diego Gamma Knife Center was established has been pleasantly unprecedented. Over 400,000 patients have been treated with Gamma Knife surgery since the procedure first came into use, and there has been zero mortality and minimal morbidity reported. Our goal is and has always been to maximize our patients’ comfort while providing an effective alternative to chemotherapy and conventional surgery.

Our tools are backed up by more than two decades of clinical research and their application in the treatment of brain disorders continues to grow. Here on our blog you’ll be able to read about some of the latest developments in the field as well as the ways in which the Gamma Knife procedure is continuing to help make neurosurgery safer and better.